Pharmacogenetic tests and depressive symptom remission: a meta-analysis of randomized controlled trials
Antidepressants are recommended for use in the treatment of moderate-to-severe major depression [1], but many patients fail to benefit from these medications. Between 30 and 50% of patients with major depressive disorder (MDD) do not respond to their first antidepressant trial [2] and remission rates are as low as 37.5% [3].
The pros and cons of preimplantation genetic testing for aneuploidy: clinical and laboratory perspectives
Aneuploidy is a major source of adverse outcomes in human reproduction. The impact is so severe, that the American College of Obstetricians and Gynecologists and the Society for Maternal-Fetal Medicine now recommend.
Preimplantation genetic diagnosis (PGD) and genetic testing for aneuploidy (PGT-A): status and future challenges
The world’s first in vitro fertilization (IVF) baby was born in July 1978 in the UK. Since then, more than 7 million infants have been born worldwide as a result of IVF. Preimplantation genetic diagnosis (PGD) was introduced in the late 1980s for couples at risk of transmitting a genetic abnormality to their children. From the mid-1990s, this technology has been employed as an embryo selection tool for patients undergoing IVF and has been known as preimplantation genetic screening (PGS). The aim of this practice has been to identify and select euploid embryos for transfer, in order to increase efficacy of IVF cycle, ensure higher implantation rates or at least decreased time to pregnancy.